Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214565 · ClinicalTrials.gov registry record · Phase 3
GALLANT 6 Tesaglitazar vs. Pioglitazone
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,450
- Enrollment target
NCT00214565 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,450 participants.
The verdict
NCT00214565, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,450 participants
- Enrollment target
Study Summary
This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.
Interventions
- DRUG Galida
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,450 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214565
The ClinicalTrials.gov registry entry for NCT00214565 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galida is the first listed.
NCT00214565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214565 about?
NCT00214565 is a clinical study titled "GALLANT 6 Tesaglitazar vs. Pioglitazone". This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, ...
What is the current status of trial NCT00214565?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,450 participants. The study started on 2004-08. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00214565?
The interventions under investigation include: Galida (DRUG).
Who is sponsoring clinical trial NCT00214565?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.